lupus nephritis – Medxy AI

Quality indicators for lupus nephritis care: implementing the 2025 EULAR recommendations — development, adherence, and impact on outcomes

By MedXY 10/16/2026

A validated set of 17 quality indicators (QIs) for lupus nephritis, derived from the 2025 EULAR recommendations, shows variable adherence in practice and an association between higher adherence and lower damage accrual in a tertiary-care cohort.

Nephrology news Rheumatology

Decoding Fibrosis in Lupus Nephritis: Distinct Macrophage-Fibroblast Interactions Fuel Renal Damage

By MedXY 08/17/2026

Spatially distinct macrophage subsets interact with heterogeneous myofibroblast populations in lupus nephritis, driving maladaptive fibrosis and chronic kidney injury. Identifying these fibroinflammatory circuits offers promising targets for therapy to prevent renal decline.

Nephrology news Rheumatology

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY 10/30/2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors' bone safety in this population.

Nephrology news Rheumatology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

By MedXY 10/24/2025

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis management.

$Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis$

Allergy & Immunology Clinical Updates Rheumatology Specialties

Innovative Allogeneic CD19-Targeting T Cells Show Promise in Refractory Systemic Lupus Erythematosus with Lupus Nephritis

By MedXY 09/04/2025

A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicated by lupus nephritis.

Clinical Updates news Rheumatology Specialties

Low Lupus Activity as a Predictive Target in Lupus Nephritis: A Clinical Appraisal of LLDAS

By MedXY 07/30/2025

Achieving low lupus disease activity (LLDAS) at 12 months is an attainable target in lupus nephritis and independently predicts reduced relapse risk and preserved renal function, supporting its potential as a future treatment goal.